Shire Plc has taken further steps to strengthen its franchise in rare diseases with an agreement to acquire privately-owned Lotus Tissue Repair Inc which has a preclinical product for the treatment of dystrophic epidermolysis bullosa (DEB). Financial terms were not disclosed.